Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...

In March, the U.S. Food and Drug Administration (FDA) announced voluntary recalls of several popular acne products due to ...

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

The FDA reported recalls of several popular acne treatments after benzene, a known carcinogen, was found in products ...

Kaya Clinics in India have launched Aerolase, a cutting-edge laser treatment for acne and scars. Known as the Neo Elite, this ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) saw its stock soar 20% after unveiling encouraging Phase 3 trial results for its acne ...

Sagimet Biosciences (NASDAQ: SGMT) stock surged 38% on premarket news of positive Phase 3 trial results for its acne therapy ...